French pharmaceutical company Servier has entered an acquisition agreement with UK-based Kaerus Bioscience to obtain rights to KER-0193, an oral small molecule drug targeting fragile X syndrome. The deal, valued at up to $450 million, accelerates Servier’s neuroscience pipeline with a novel candidate addressing a significant unmet need in developmental disorders.